Aspirin in breast cancer

A study investigated whether aspirin at 300 mg/d improved invasive disease-free survival among survivors of nonmetastatic breast cancer (1):

• randomised, placebo-controlled clinical trial included 3020 patients with high-risk nonmetastatic breast cancer
• the trial was terminated early because of lack of benefit from aspirin (hazard ratio for invasive disease-free survival for aspirin vs placebo, 1.27 [not statistically significant])
  • although the trial was planned for 5 years, it was suspended at the first interim safety analysis (median follow-up, 33.8 months; range, 0.1-72.6) because the results indicated futility: 141 vs 112 invasive disease-free events in the aspirin vs placebo group, respectively (hazard ratio, 1.27; 95% CI, 0.99-1.63; P = 0.06)
• study authors concluded:
  • among participants with high-risk nonmetastatic breast cancer, daily aspirin therapy did not improve risk of breast cancer recurrence or survival in early follow-up

Reference:

1. Chen WY, Ballman KV, Partridge AH, et al. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial. JAMA. Published online April 29, 2024. doi:10.1001/jama.2024.4840